Analysis of French generic medicines retail market: why the use of generic medicines is limited

References

• Chevreul K, Durand-Zaleski I, Bahrami S, et al. France: health system review. Health Syst Transit 2010;12(6):1-291
   PubMedGoogle Scholar
• Steffen M. The French health care system: liberal universalism. J Health Polit Policy Law 2010;35(3):353-87
   PubMed Web of Science ®Google Scholar
• Delcroix Lopes S, Marty C, Berdai D. PHIS Pharma Profile: France. 2011
   Google Scholar
• Bellanger M, Mossé P. The search for the Holy Grail: combining decentralised planning and contracting mechanisms in the French health care system. Health Econ 2005;14:S119-32
   PubMed Web of Science ®Google Scholar
• Le Pen C. The drug budget silo mentality: the French case. Value Health 2003;6(1):10-19
   Google Scholar
• Paris V. Pharmaceutical regulation in France 1980-2003. Int J Health Plann Manage 2005;20(4):307-28
   PubMed Web of Science ®Google Scholar
• Lochouarn M. France launches new drug regulatory agency. Lancet 2012;379:2136
   PubMed Web of Science ®Google Scholar
• Rémuzat C, Toumi M, Falissard B. New drug regulations in France: what are the impacts on market access? Part 1 - overview of new drug regulations in France. J Market Access Health Policy 2013;1:20891
   PubMedGoogle Scholar
• Carone G, Schwierz C, Xavier A. Cost-containment policies in public pharmaceutical spending in the EU.Economic papers 461 September. 2012;2012:1-64
   Google Scholar
• Mutualité Française. [Medication: unprecedented decline in spending in 2012]. 2013
   Google Scholar
• CBI. CBI market survey: the pharmaceutical products market in the EU. 2010;1-46
   Google Scholar
• Organisation for economic co-operation and development. OECD health data 2013. 2013
   Google Scholar
• Gumbs P, Verschuren M, Souverein P, et al. Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution. Br J Clin Pharmacol 2007;64(5):680-5
   PubMed Web of Science ®Google Scholar
• GERS: Groupement pour l’Elaboration et la Réalisation de Statistiques. GERS database. 2014
   Google Scholar
• Habl C, Antony K, Arts D, et al. Surveying, assessing and analysing the pharmaceutical sector in the 25 EU Member States. 2006. 1-794
   Google Scholar
• European Commission. Pharmaceutical sector inquiry: final report 2009. 1-533
   Google Scholar
• GaBi. Country focus: France. GaBi online - generics and biosimilars initiative. 2012
   Google Scholar
• Generics Bulletin. French pricing obsession is a threat to penetration. Generics Bulletin 2012;2012:22-3
   Google Scholar
• Sermet C, Andrieu V, Godman B, et al. Ongoing pharmaceutical reforms in France: implications for key stakeholders. Appl Health Econ Health Policy 2010;8(1):7-24
   PubMedGoogle Scholar
• European Generic Medicines Association. 2011 market review. 2011
   Google Scholar
• Imbaud D, Morin A, Picard S, Toujas F. Evaluation de la politique française des médicaments génériques. 2012; RM2012-115P
   Google Scholar
• CEPS. Comite économique des produitds de santé: Rapport d’activité 2012. 2012
   Google Scholar
• Konijn P. Pharmaceutical products - comparative price levels in 33 European countries in 2005. 2007
   Google Scholar
• IMS Health. Analyse des prix des génériques en Europe. 2014
   Google Scholar
• Vogler S. How large are the differences between originator and generic prices? Analysis of five molecules in 16 European countries. Farmeconomia: Health Econ Therap Pathways 2012;13(3):29-41
   Google Scholar
• Godman B, Bishop I, Finlayson A, et al. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Rev Pharmacoecon Outcomes Res 2013;13(4):469-82
   PubMed Web of Science ®Google Scholar
• Delcroix-Lopes S, van der Erf S. Coût des génériques en Europe et mécanismes de régulation des prix en Allemagne, en Angleterre et aux Pays-Bas. Points de repère 2012. 2012; numéro 39
   Google Scholar
• Reinaud F. Generic drug price trends - a comparison across France, Germany, Italy, Spain and the UK. Available from: http://healthcare.blogs.ihs.com/2012/01/06/generic-drug-price-trends-france-germany-italy-spain-uk/2012
   Google Scholar
• Generics Bulletin. France must focus on penetration not price. Generics Bulletin 2013;13
   Google Scholar
• Generics Bulletin. France intends to slash prices. News@Genericsbulletin3. 2013;469:2
   Google Scholar
• Grandfils N. Implementation of reference prices: France. 2005
   Google Scholar
• Simoens S, De Coster S. Sustaining generic medicines markets in Europe. 2006;1-100
   Google Scholar
• Allenet B, Barry H. Opinion and behaviour of pharmacists towards the substitution of branded drugs by generic drugs: survey of 1,000 French community pharmacists. Pharmaceutical World Sci 2003;25(5):197-202
   PubMedGoogle Scholar
• Lagarce L, Lusson-Brisset C, Bruhat C, et al. [How practitioners view generic drugs: an opinion study from general practitioners in Maine-et-Loire (France)]. Therapie 2005;60(1):67-74
   PubMed Web of Science ®Google Scholar
• Autorité de la concurrence. The Autorité de la concurrence fines Sanofi-Aventis a total of €40.6 million for disparaging the generic versions of Plavix, one of the world’s best selling medicines. Available from: www.autoritedelaconcurrence.fr/user/standard.php?id_rub=483&id_article=2091 2013
   Google Scholar
• Baumgärtel C, Godman B, Malmström R, et al. What lessons can be learned from the launch of generic clopidogrel. GaBi Journal 2012;1(2):58-68
   Google Scholar
• Pichetti S, Sermet C, Godman B, et al. Multiple-sourced statin prescribing in France. Appl Health Econ Health Policy 2013;11(3):205-18
   PubMedGoogle Scholar
• Dylst P, Vulto A, Simoens S. Demand-side policies to encourage the use of generic medicines: an overview. Expert Rev Pharmacoecon Outcomes Res 2013;13(1):59-72
   PubMed Web of Science ®Google Scholar
• Sécurité Sociale. Extrait du rapport de la commission des Comptes de Sécurité sociale (septembre 2011): Fiche éclairage "maladie. 2011
   Google Scholar
• Ulmann P. [Remuneration of physicians on public health objectives: first results and advances of the medical convention]. 2011
   Google Scholar
• Biga J, Taboulet F, Lapeyre-Mestre M, et al. Montastruc J. [Prescribing drug by international non-proprietary name: the perception of health and non-health professionals]. Therapie 2005;60(4):401-7
   PubMed Web of Science ®Google Scholar
• Paraponaris A, Verger P, Desquins B, et al. Delivering generics without regulatory incentives? Empirical evidence from French general practitioners about willingness to prescribe international non-proprietary names. Health Policy 2004;70:23-32
   PubMed Web of Science ®Google Scholar
• Rémuzat C, Toumi M, Falissard B. New drug regulations in France: what are the impacts on market access? Part 2 - impacts on market access and impacts for the pharmaceutical industry. J Market Access Health Policy 2013;1:20892
   Google Scholar
• Hallouard F, Bontemps H, Denis I, et al. [The pharmaceutical dispensation of drug in France. Part I: state of the French regulation]. Médecine Droit 2012;2012:127-57
   Google Scholar
• Mutualité Française. Barometre de la prescription en DCI (Dénomination Commune Internationale). 2013
   Google Scholar
• Bras PL, Ricordeau P, Roussille B, Saintoyant V. L’information des médecins généralistes sur le médicament. 2007
   Google Scholar
• Generics Bulletin. France’s fortunes falter as répertoire sales shrink. Generics Bulletin 2012;2012:26-7
   Google Scholar
• Garattini L, Tediosi F. A comparative analysis of generics markets in five European countries. Health Policy 2000;51:149-62
   PubMed Web of Science ®Google Scholar
• Agence national de sécurité du médicament et des produits de santé. Répertoire des groupes génériques. 2013;1-659
   Google Scholar
• Agence national de sécurité du médicament et des produits de santé. Les médicaments génériques: des médicaments à part entière. 2012
   Google Scholar
• Mossialos E, Oliver A. An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom. Int J Health Planning Manage 2005;20:291-306
   PubMed Web of Science ®Google Scholar
• Mossialos E, Walley T, Rudisill C. Provider incentives and prescribing behavior in Europe. Expert RevPharmacoecon Outcomes Res 2005;5(1):81-93
   PubMedGoogle Scholar
• Dylst P, Vulto A, Simoens S. How can pharmacist remuneration systems in Europe contribute to generic medicine dispensing? Pharmacy Practice 2012;10(1):3-8
   PubMedGoogle Scholar
• Kanavos P, Taylor D. Pharmacy discounts on generic medicines in France: is there room for further efficiency savings? Curr Med Res Opin 2007;23(10):2467-76
   PubMed Web of Science ®Google Scholar
• Peny JM. What is the value of authorised generic agreements? Assessments on the French market. J Generic Med 2007;4(2):106-16
   Google Scholar
• Pidoux E. Responsabilité médicin/pharmacien au regard des génériques: une substitution de responsabilité? Médecine Droit 2013;47:10-14
   Google Scholar
• Generics Bulletin. French body blames doctors for rate slide. Generics Bulletin 2012;2012:10
   Google Scholar
• Grandfils N, Sermet C. Pharmaceutical policy in France: a mosaic of reforms. Eurohealth 2006;12(3):15-17
   Google Scholar
• Menkès C, Jinot CI. Place des génériques dans la prescription. 2012;1:7
   Google Scholar
• Generics Bulletin. French sales lifted by incentive scheme. Generics Bulletin 2013;12
   Google Scholar
• Generics Bulletin. French survey sees a drop in confidence. Generics Bulletin 2013;8
   Google Scholar
• Generics Bulletin. French study shows need for awareness. News@Genericsbulletin 2013;479:7
   Google Scholar
• IMS Health. MIDAS Database. 2013
   Google Scholar
• GEMME. [The responses of GEMME to the report of the National Academy of Medicine on generics drugs]. 2012
   Google Scholar
• Chu C, Rudant E, Bonvalet M, et al. Generic drug prescriptions following hospital discharge: a prospective study in France. Eur J Intern Med 2011;22:e45-9
   Web of Science ®Google Scholar
• Godman B, Abuelkhair M, Vitry A, et al. Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach. GaBi J 2012;1(2):69-83
   Google Scholar
• Godman B, Bennie M, Baumgärtel C, et al. Essential to increase the use of generics in Europe to maintain comprehensive health care. Farmeconomia: Health Econ Therap Pathways 2012;13(3):5-20
   Google Scholar
• Generics Bulletin. French savings reach EUR2.4 billion. Generics Bulletin 2014
   Google Scholar